July 28, 2006 – Barrier Therapeutics received FDA approval for Xolegel, a treatment for seborrheic dermatitis; in Europe, Roche and OSI Pharma lost a decision to use Tarceva against pancreatic cancer; Genitope fell sharply after the data monitoring board failed to recommend an early stop to Phase III trial of MyVax; Schering-Plough received European approval for Suboxone tablets for opioid dependence; Epix Pharma said the FDA will take extra time to review its appeal of Vasovist; Inova Trauma Center has withdrawn from participating in a Phase III trial of PolyHeme, a synthetic blood subsistute developed by Northfield Labs; and Pharming won Fast Track Designation for its hereditary angioedema drug. The Centient Biotech 200™ moved 18 points higher to 3655.46, a rise of .50%. More details...
